DAFTAR PUSTAKA

Arita, H. *et al.* (2013) "Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss," *Acta Neuropathologica*, 126(2), pp. 267–276. Available at: https://doi.org/10.1007/s00401-013-1141-6.

Arita, H. *et al.* (2016) "A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas," *Acta Neuropathologica Communications*, 4(1), p. 79. Available at: https://doi.org/10.1186/s40478-016-0351-2.

Bauman, G. *et al.* (1999) "Low grade glioma: a measuring radiographic response to radiotherapy.," *The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques*, 26(1), pp. 18–22.

Becker, T. and Haferkamp, S. (2013) "Molecular Mechanisms of Cellular Senescence," in *Senescence and Senescence-Related Disorders*. InTech. Available at: https://doi.org/10.5772/54120.

van den Bent, M.J., Bromberg, J.E.C. and Buckner, J. (2016) "Low-grade and anaplastic oligodendroglioma," in, pp. 361–380. Available at: https://doi.org/10.1016/B978-0-12-802997-8.00022-0.

Bettegowda, C. *et al.* (2014) "Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies," *Science Translational Medicine*, 6(224). Available at: https://doi.org/10.1126/scitranslmed.3007094.

Bhatia, A. *et al.* (2024) "Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma," *Clinical Cancer Research*, 30(1), pp. 106–115. Available at: https://doi.org/10.1158/1078-0432.CCR-23-1180.

Blackburn, E.H. (2005) "Telomeres and telomerase: their mechanisms of action and the effects of altering their functions," *FEBS Letters*, 579(4), pp. 859–862. Available at: https://doi.org/10.1016/j.febslet.2004.11.036.

Bleeker, F.E. *et al.* (2010) "The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma," *Acta Neuropathologica*, 119(4), pp. 487–494. Available at: https://doi.org/10.1007/s00401-010-0645-6.

Boele, F.W. *et al.* (2020) "Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms.," *Journal of neuro-oncology*, 147(2), pp. 485–494. Available at: https://doi.org/10.1007/s11060-020-03454-3.

Brandner, S. *et al.* (2022) "Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane

systematic review," *Neuropathology and Applied Neurobiology*, 48(4). Available at: https://doi.org/10.1111/nan.12790.

Brasil Caseiras, G. *et al.* (2009) "Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient.," *Radiology*, 253(2), pp. 505–12. Available at: https://doi.org/10.1148/radiol.2532081623.

Brennan, C.W. *et al.* (2013) "The Somatic Genomic Landscape of Glioblastoma," *Cell*, 155(2), pp. 462–477. Available at: https://doi.org/10.1016/j.cell.2013.09.034.

Broccoli, D., Young, J.W. and de Lange, T. (1995) "Telomerase activity in normal and malignant hematopoietic cells.," *Proceedings of the National Academy of Sciences*, 92(20), pp. 9082–9086. Available at: https://doi.org/10.1073/pnas.92.20.9082.

Byun, Y.H. and Park, C.-K. (2022) "Classification and Diagnosis of Adult Glioma: A Scoping Review," *Brain & Neurorehabilitation*, 15(3). Available at: https://doi.org/10.12786/bn.2022.15.e23.

Calvert, A.E. *et al.* (2017) "Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation," *Cell Reports*, 19(9), pp. 1858–1873. Available at: https://doi.org/10.1016/j.celrep.2017.05.014.

Carpenter, G. and Cohen, S. (1979) "Epidermal Growth Factor," *Annual Review of Biochemistry*, 48(1), pp. 193–216. Available at: https://doi.org/10.1146/annurev.bi.48.070179.001205.

Carrano, A. *et al.* (2021) "Sex-Specific Differences in Glioblastoma.," *Cells*, 10(7). Available at: https://doi.org/10.3390/cells10071783.

Chen, Z. *et al.* (2021) "Comprehensive Analysis Revealed that CDKN2A is a Biomarker for Immune Infiltrates in Multiple Cancers," *Frontiers in Cell and Developmental Biology*, 9. Available at: https://doi.org/10.3389/fcell.2021.808208.

Coons, S.W. *et al.* (1997) "Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.," *Cancer*, 79(7), pp. 1381–93. Available at: https://doi.org/10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncr16>3.0.co;2-w.

Crossley, B.M. *et al.* (2020) "Guidelines for Sanger sequencing and molecular assay monitoring.," *Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc*, 32(6), pp. 767–775. Available at: https://doi.org/10.1177/1040638720905833.

Dempsey, M.F., Condon, B.R. and Hadley, D.M. (2005) "Measurement of tumor 'size' in recurrent malignant glioma: 1D, 2D, or 3D?," *AJNR. American journal of neuroradiology*, 26(4), pp. 770–6.

Eckel-Passow, J.E. *et al.* (2015) "Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.," *The New England journal of medicine*, 372(26), pp. 2499–508. Available at: https://doi.org/10.1056/NEJMoa1407279.

Ellingson, B.M. *et al.* (2016) "Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma," *Cancer*, 122(11), pp. 1718–1727. Available at: https://doi.org/10.1002/cncr.29957.

Ertl-Wagner, B.B. *et al.* (2009) "Reliability of tumor volume estimation from MR images in patients with malignant glioma. Results from the American College of Radiology Imaging Network (ACRIN) 6662 Trial.," *European radiology*, 19(3), pp. 599–609. Available at: https://doi.org/10.1007/s00330-008-1191-7.

Fan, Z. *et al.* (2020a) "Association of tumor growth rates with molecular biomarker status: a longitudinal study of high-grade glioma," *Aging*, 12(9), pp. 7908–7926. Available at: https://doi.org/10.18632/aging.103110.

Fan, Z. *et al.* (2020b) "Association of tumor growth rates with molecular biomarker status: a longitudinal study of high-grade glioma," *Aging*, 12(9), pp. 7908–7926. Available at: https://doi.org/10.18632/aging.103110.

Fan, Z. *et al.* (2020c) "Association of tumor growth rates with molecular biomarker status: a longitudinal study of high-grade glioma," *Aging*, 12(9), pp. 7908–7926. Available at: https://doi.org/10.18632/aging.103110.

Ge, J. *et al.* (2020) "Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas.," *International journal of clinical and experimental pathology*, 13(2), pp. 230–238.

Ghosh, H.S. *et al.* (2025) "Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors.," *Neuro-oncology*, 27(1), pp. 195–208. Available at: https://doi.org/10.1093/neuonc/noae164.

Gladson, C.L., Prayson, R.A. and Liu, W.M. (2010) "The Pathobiology of Glioma Tumors," *Annual Review of Pathology: Mechanisms of Disease*, 5(1), pp. 33–50. Available at: https://doi.org/10.1146/annurev-pathol-121808-102109.

Green, S. *et al.* (2022) "Characterization of pediatric brain tumors using pre-diagnostic neuroimaging.," *Frontiers in oncology*, 12, p. 977814. Available at: https://doi.org/10.3389/fonc.2022.977814.

'GULLICK, W.; 'MARSDEN, J.; 'WHITTLE, N.; 'WARD, B.; 'BOBROW, L.; 'WATERFIELD, M. (1986) "EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTORS ON HUMAN CERVICAL, OVARIAN,

AND VULVAR CARCINOMAS," *CANCER RESEARCH*, 46(1), pp. 285–292.

Han, S. *et al.* (2020) "IDH mutation in glioma: molecular mechanisms and potential therapeutic targets," *British Journal of Cancer*, 122(11), pp. 1580–1589. Available at: https://doi.org/10.1038/s41416-020-0814-x.

Haseltine, J.M. *et al.* (2022) "Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancer," *Translational Lung Cancer Research*, 11(8), pp. 1578–1590. Available at: https://doi.org/10.21037/tlcr-22-164.

Hayflick, L. (1965) "The limited in vitro lifetime of human diploid cell strains," *Experimental Cell Research*, 37(3), pp. 614–636. Available at: https://doi.org/10.1016/0014-4827(65)90211-9.

Heidenreich, B. *et al.* (2015) "*TERT* promoter mutations and telomere length in adult malignant gliomas and recurrences," *Oncotarget*, 6(12), pp. 10617–10633. Available at: https://doi.org/10.18632/oncotarget.3329.

Hernández-Ochoa, B. *et al.* (2021) "Validation and Selection of New Reference Genes for RT-qPCR Analysis in Pediatric Glioma of Different Grades.," *Genes*, 12(9). Available at: https://doi.org/10.3390/genes12091335.

Hindson, B.J. *et al.* (2011) "High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number," *Analytical Chemistry*, 83(22), pp. 8604–8610. Available at: https://doi.org/10.1021/ac202028g.

Horbinski, C. *et al.* (2011) "EGFR expression stratifies oligodendroglioma behavior.," *The American journal of pathology*, 179(4), pp. 1638–44. Available at: https://doi.org/10.1016/j.ajpath.2011.06.020.

Huang, D.-S. *et al.* (2015) "Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation," *European Journal of Cancer*, 51(8), pp. 969–976. Available at: https://doi.org/10.1016/j.ejca.2015.03.010.

Huang, F.W. *et al.* (2013) "Highly Recurrent *TERT* Promoter Mutations in Human Melanoma," *Science*, 339(6122), pp. 957–959. Available at: https://doi.org/10.1126/science.1229259.

Huang, F.W. *et al.* (2015) "TERT promoter mutations and monoallelic activation of TERT in cancer," *Oncogenesis*, 4(12), pp. e176–e176. Available at: https://doi.org/10.1038/oncsis.2015.39.

Huang, L.E. (2019) "Friend or foe-IDH1 mutations in glioma 10 years on.," *Carcinogenesis*, 40(11), pp. 1299–1307. Available at: https://doi.org/10.1093/carcin/bgz134.

Huang, R.Y. *et al.* (2020) "Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment,"

Neuro-Oncology, 22(12), pp. 1822–1830. Available at: https://doi.org/10.1093/neuonc/noaa105.

Hudson, J.M. *et al.* (2022) "Impact of MGMT Promoter Methylation Status on Tumor Dynamics during Weekly Adaptive Radiotherapy for Glioblastoma," *International Journal of Radiation Oncology*Biology*Physics*, 114(3), pp. S62–S63. Available at: https://doi.org/10.1016/j.ijrobp.2022.07.448.

Iliadis, G. *et al.* (2012) "Volumetric and MGMT parameters in glioblastoma patients: Survival analysis," *BMC Cancer*, 12(1), p. 3. Available at: https://doi.org/10.1186/1471-2407-12-3.

Jaiswal, S. (2016) "Role of immunohistochemistry in the diagnosis of central nervous system tumors," *Neurology India*, 64(3), p. 502. Available at: https://doi.org/10.4103/0028-3886.181547.

Jang, B. *et al.* (2024) "Integrative multi-omics characterization reveals sex differences in glioblastoma," *Biology of Sex Differences*, 15(1), p. 23. Available at: https://doi.org/10.1186/s13293-024-00601-7.

Jia, Z. *et al.* (2022) "Exploring the relationship between age and prognosis in glioma: rethinking current age stratification.," *BMC neurology*, 22(1), p. 350. Available at: https://doi.org/10.1186/s12883-022-02879-9.

Jiang, S., Zanazzi, G.J. and Hassanpour, S. (2021) "Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images," *Scientific Reports*, 11(1), p. 16849. Available at: https://doi.org/10.1038/s41598-021-95948-x.

Jorissen, R. (2003) "Epidermal growth factor receptor: mechanisms of activation and signalling," *Experimental Cell Research*, 284(1), pp. 31–53. Available at: https://doi.org/10.1016/S0014-4827(02)00098-8.

Kaloshi, G. *et al.* (2007) "Temozolomide for low-grade gliomas," *Neurology*, 68(21), pp. 1831–1836. Available at: https://doi.org/10.1212/01.wnl.0000262034.26310.a2.

Kapoor, M. and Gupta, V. (2024) *Astrocytoma*.

Karamani, L. *et al.* (2023) "Tumor size, treatment patterns, and survival in neuro-oncology patients before and during the COVID-19 pandemic," *Neurosurgical Review*, 46(1), p. 226. Available at: https://doi.org/10.1007/s10143-023-02132-y.

Kessler, J. *et al.* (2015) "IDH1R132H mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status," *Radiotherapy and Oncology*, 116(3), pp. 381–387. Available at: https://doi.org/10.1016/j.radonc.2015.08.007.

Khan, I., Waqas, M. and Shamim, M.S. (2017) "Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.," *JPMA. The Journal of the Pakistan Medical Association*, 67(5), pp. 816–817.

Koivunen, P. *et al.* (2012) "Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation," *Nature*, 483(7390), pp. 484–488. Available at: https://doi.org/10.1038/nature10898.

Labussiere, M. *et al.* (2010) "IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?," *The oncologist*, 15(2), pp. 196–9. Available at: https://doi.org/10.1634/theoncologist.2009-0218.

Lee, J.C. *et al.* (2006) "Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain," *PLoS Medicine*, 3(12), p. e485. Available at: https://doi.org/10.1371/journal.pmed.0030485.

Lee, S.C. (2018) "Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics," *Archives of Pathology & Laboratory Medicine*, 142(7), pp. 804–814. Available at: https://doi.org/10.5858/arpa.2017-0449-RA.

Levine, A.B. *et al.* (2020) "Ependymoma and Chordoma," *Neurosurgery*, 87(5), pp. 860–870. Available at: https://doi.org/10.1093/neuros/nyaa329.

Li, X. *et al.* (2016) "PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma," *Oncotarget*, 7(22), pp. 33440–33450. Available at: https://doi.org/10.18632/oncotarget.7961.

Lin, L. *et al.* (2021) "Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.," *Cancer research and treatment*, 53(2), pp. 367–377. Available at: https://doi.org/10.4143/crt.2020.506.

Lin, Z. *et al.* (2020) "Establishment of age group classification for risk stratification in glioma patients.," *BMC neurology*, 20(1), p. 310. Available at: https://doi.org/10.1186/s12883-020-01888-w.

Louis, D.N. *et al.* (2021) "The 2021 WHO Classification of Tumors of the Central Nervous System: a summary," *Neuro-Oncology*, 23(8), pp. 1231–1251. Available at: https://doi.org/10.1093/neuonc/noab106.

Lu, V.M. *et al.* (2019) "Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry," *Clinical Neurology and Neurosurgery*, 182, pp. 32–36. Available at: https://doi.org/10.1016/j.clineuro.2019.04.027.

Lu, V.M. *et al.* (2020a) "The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature," *Journal of Neuro-Oncology*, 148(2), pp. 221–229. Available at: https://doi.org/10.1007/s11060-020-03528-2.

Lu, V.M. *et al.* (2020b) "The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature," *Journal of Neuro-Oncology*, 148(2), pp. 221–229. Available at: https://doi.org/10.1007/s11060-020-03528-2.

Mair, R. and Mouliere, F. (2022) "Cell-free DNA technologies for the analysis of brain cancer," *British Journal of Cancer*, 126(3), pp. 371–378. Available at: https://doi.org/10.1038/s41416-021-01594-5.

Mazzocco, P. *et al.* (2015) "Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics," *CPT: Pharmacometrics & Systems Pharmacology*, 4(12), pp. 728–737. Available at: https://doi.org/10.1002/psp4.54.

Mesfin, F.B. and Al-Dhahir, M.A. (2024a) *Gliomas*.

Mesfin, F.B. and Al-Dhahir, M.A. (2024b) *Gliomas*.

Miller, J.J. (2022) "Targeting IDH-Mutant Glioma," *Neurotherapeutics*, 19(6), pp. 1724–1732. Available at: https://doi.org/10.1007/s13311-022-01238-3.

Miotke, L. *et al.* (2014) "High Sensitivity Detection and Quantitation of DNA Copy Number and Single Nucleotide Variants with Single Color Droplet Digital PCR," *Analytical Chemistry*, 86(5), pp. 2618–2624. Available at: https://doi.org/10.1021/ac403843j.

Momeni, F. *et al.* (2021) "Differentiating Between Low- and High-grade Glioma Tumors Measuring Apparent Diffusion Coefficient Values in Various Regions of the Brain.," *Oman medical journal*, 36(2), p. e251. Available at: https://doi.org/10.5001/omj.2021.59.

Muralidharan, K. *et al.* (2021) "*TERT* Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas," *Clinical Cancer Research*, 27(1), pp. 169–178. Available at: https://doi.org/10.1158/1078-0432.CCR-20-3083.

Nakagawachi, T. *et al.* (2003) "Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer," *Oncogene*, 22(55), pp. 8835–8844. Available at: https://doi.org/10.1038/sj.onc.1207183.

Nakasu, S. *et al.* (2005) "Growth pattern changes of meningiomas: long-term analysis.," *Neurosurgery*, 56(5), pp. 946–55; discussion 946-55.

Nelson, E.J. *et al.* (2023) "Clinical Evaluation of IDH Mutation Status in Formalin-Fixed Paraffin-Embedded Tissue in Gliomas.," *Molecular diagnosis & therapy*, 27(3), pp. 371–381. Available at: https://doi.org/10.1007/s40291-022-00638-7.

Ni, Y. *et al.* (2022) "The Roles of IDH1 in Tumor Metabolism and Immunity," *Future Oncology*, 18(35), pp. 3941–3953. Available at: https://doi.org/10.2217/fon-2022-0583.

Nikiforova, M.N. and Hamilton, R.L. (2011) "Molecular Diagnostics of Gliomas," *Archives of Pathology & Laboratory Medicine*, 135(5), pp. 558–568. Available at: https://doi.org/10.5858/2010-0649-RAIR.1.

Olympios, N. *et al.* (2021) "TERT Promoter Alterations in Glioblastoma: A Systematic Review," *Cancers*, 13(5), p. 1147. Available at: https://doi.org/10.3390/cancers13051147.

Ostrom, Q.T. *et al.* (2014) "The epidemiology of glioma in adults: a 'state of the science' review.," *Neuro-oncology*, 16(7), pp. 896–913. Available at: https://doi.org/10.1093/neuonc/nou087.

Ostrom, Q.T. *et al.* (2020) "CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.," *Neuro-oncology*, 22(12 Suppl 2), pp. iv1–iv96. Available at: https://doi.org/10.1093/neuonc/noaa200.

Palpan Flores, A. *et al.* (2020) "Assessment of Pre-operative Measurements of Tumor Size by MRI Methods as Survival Predictors in Wild Type IDH Glioblastoma," *Frontiers in Oncology*, 10. Available at: https://doi.org/10.3389/fonc.2020.01662.

Park, Y.W., Vollmuth, P., Foltyn-Dumitru, M., Sahm, F., Ahn, S.S., *et al.* (2023a) "The 2021 <scp>WHO</scp> Classification for Gliomas and Implications on Imaging Diagnosis: Part 1—Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas," *Journal of Magnetic Resonance Imaging*, 58(3), pp. 677–689. Available at: https://doi.org/10.1002/jmri.28743.

Park, Y.W., Vollmuth, P., Foltyn-Dumitru, M., Sahm, F., Ahn, S.S., *et al.* (2023b) "The 2021 <scp>WHO</scp> Classification for Gliomas and Implications on Imaging Diagnosis: Part 2—Summary of Imaging Findings on Pediatric-Type Diffuse High-Grade Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Circumscribed Astrocytic Gliomas," *Journal of Magnetic Resonance Imaging*, 58(3), pp. 690–708. Available at: https://doi.org/10.1002/jmri.28740.

Park, Y.W., Vollmuth, P., Foltyn-Dumitru, M., Sahm, F., Choi, K.S., *et al.* (2023) "The 2021 <scp>WHO</scp> Classification for Gliomas and Implications on Imaging Diagnosis: Part 3—Summary of Imaging Findings on Glioneuronal and Neuronal Tumors," *Journal of Magnetic Resonance Imaging*, 58(6), pp. 1680–1702. Available at: https://doi.org/10.1002/jmri.29016.

Pinkham, M.B. *et al.* (2015) "FISHing Tips: What Every Clinician Should Know About 1p19q Analysis in Gliomas Using Fluorescence in situ Hybridisation,"

Clinical Oncology, 27(8), pp. 445–453. Available at: https://doi.org/10.1016/j.clon.2015.04.008.

Provenzale, J.M., Ison, C. and Delong, D. (2009) "Bidimensional measurements in brain tumors: assessment of interobserver variability.," *AJR. American journal of roentgenology*, 193(6), pp. W515-22. Available at: https://doi.org/10.2214/AJR.09.2615.

Provenzale, J.M. and Mancini, M.C. (2012) "Assessment of intra-observer variability in measurement of high-grade brain tumors.," *Journal of neuro-oncology*, 108(3), pp. 477–83. Available at: https://doi.org/10.1007/s11060-012-0843-2.

Rasheed, S., Rehman, K. and Akash, M.S.H. (2021) "An insight into the risk factors of brain tumors and their therapeutic interventions," *Biomedicine & Pharmacotherapy*, 143, p. 112119. Available at: https://doi.org/10.1016/j.biopha.2021.112119.

Reeves, G.I. and Marks, J.E. (1979) "Prognostic Significance of Lesion Size for Glioblastoma Multiforme," *Radiology*, 132(2), pp. 469–472. Available at: https://doi.org/10.1148/132.2.469.

Reifenberger, G. *et al.* (2017) "Advances in the molecular genetics of gliomas — implications for classification and therapy," *Nature Reviews Clinical Oncology*, 14(7), pp. 434–452. Available at: https://doi.org/10.1038/nrclinonc.2016.204.

Salari, N. *et al.* (2023) "The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis," *European Journal of Medical Research*, 28(1), p. 39. Available at: https://doi.org/10.1186/s40001-023-01011-y.

Sales, A.H.A. *et al.* (2019) "Role of postoperative tumor volume in patients with MGMT-unmethylated glioblastoma," *Journal of Neuro-Oncology*, 142(3), pp. 529–536. Available at: https://doi.org/10.1007/s11060-019-03124-z.

Sejda, A. *et al.* (2022) "WHO CNS5 2021 classification of gliomas: a practical review and road signs for diagnosing pathologists and proper patho-clinical and neuro-oncological cooperation," *Folia Neuropathologica*, 60(2), pp. 137–152. Available at: https://doi.org/10.5114/fn.2022.118183.

Sharma, A. and Graber, J.J. (2021) "Overview of prognostic factors in adult gliomas," *Annals of Palliative Medicine*, 10(1), pp. 863–874. Available at: https://doi.org/10.21037/apm-20-640.

Singh, S. *et al.* (2021) "Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—through the looking glass!," *Egyptian Journal of Neurosurgery*, 36(1), p. 32. Available at: https://doi.org/10.1186/s41984-021-00118-w.

Singhal, S. *et al.* (2020) "Simplifying tumor volume estimation from linear dimensions for intra-cranial lesions treated with stereotactic radiosurgery," *Journal of Medical Physics*, 45(4), p. 199. Available at: https://doi.org/10.4103/jmp.JMP_56_20.

Śledzińska, P. *et al.* (2021) "Prognostic and Predictive Biomarkers in Gliomas," *International Journal of Molecular Sciences*, 22(19), p. 10373. Available at: https://doi.org/10.3390/ijms221910373.

Śledzińska, P. *et al.* (2022) "Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics.," *Molecular diagnosis & therapy*, 26(6), pp. 699–713. Available at: https://doi.org/10.1007/s40291-022-00612-3.

SMETANA JR., K. *et al.* (2016) "Ageing as an Important Risk Factor for Cancer," *Anticancer Research*, 36(10), pp. 5009–5018. Available at: https://doi.org/10.21873/anticanres.11069.

Sorensen, A.G. *et al.* (2001) "Comparison of Diameter and Perimeter Methods for Tumor Volume Calculation," *Journal of Clinical Oncology*, 19(2), pp. 551–557. Available at: https://doi.org/10.1200/JCO.2001.19.2.551.

Sreenivasan, S. *et al.* (2016) "Measuring glioma volumes: A comparison of linear measurement based formulae with the manual image segmentation technique," *Journal of Cancer Research and Therapeutics*, 12(1), p. 161. Available at: https://doi.org/10.4103/0973-1482.153999.

Stensjøen, A.L. *et al.* (2015) "Growth dynamics of untreated glioblastomas in vivo," *Neuro-Oncology*, 17(10), pp. 1402–1411. Available at: https://doi.org/10.1093/neuonc/nov029.

Sun, T. *et al.* (2015) "An integrative view on sex differences in brain tumors.," *Cellular and molecular life sciences : CMLS*, 72(17), pp. 3323–42. Available at: https://doi.org/10.1007/s00018-015-1930-2.

Szylberg, M. *et al.* (2022) "MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study," *Biomedicines*, 10(8), p. 2030. Available at: https://doi.org/10.3390/biomedicines10082030.

Tork, C.A. and Atkinson, C. (2024) *Oligodendroglioma*.

Torp, S.H., Solheim, O. and Skjulsvik, A.J. (2022) "The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview," *Acta Neurochirurgica*, 164(9), pp. 2453–2464. Available at: https://doi.org/10.1007/s00701-022-05301-y.

Tran, A.N. *et al.* (2014) "Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry," *Neuro-Oncology*, 16(3), pp. 414–420. Available at: https://doi.org/10.1093/neuonc/not198.

Vaidyanathan, M. *et al.* (1995) "Comparison of supervised MRI segmentation methods for tumor volume determination during therapy.," *Magnetic resonance imaging*, 13(5), pp. 719–28. Available at: https://doi.org/10.1016/0730-725x(95)00012-6.

Varn, F.S. *et al.* (2022a) "Glioma progression is shaped by genetic evolution and microenvironment interactions," *Cell*, 185(12), pp. 2184-2199.e16. Available at: https://doi.org/10.1016/j.cell.2022.04.038.

Varn, F.S. *et al.* (2022b) "Glioma progression is shaped by genetic evolution and microenvironment interactions," *Cell*, 185(12), pp. 2184-2199.e16. Available at: https://doi.org/10.1016/j.cell.2022.04.038.

Wefel, J.S. *et al.* (2016) "Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.," *Neuro-oncology*, 18(12), pp. 1656–1663. Available at: https://doi.org/10.1093/neuonc/now165.

Whitmire, P. *et al.* (2020) "Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients.," *BMC cancer*, 20(1), p. 447. Available at: https://doi.org/10.1186/s12885-020-06816-2.

Wood, J.R., Green, S.B. and Shapiro, W.R. (1988) "The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group.," *Journal of Clinical Oncology*, 6(2), pp. 338–343. Available at: https://doi.org/10.1200/JCO.1988.6.2.338.

Yan, D. *et al.* (2022) "Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma," *Frontiers in Immunology*, 13. Available at: https://doi.org/10.3389/fimmu.2022.914618.

Yang, K. *et al.* (2022) "Glioma targeted therapy: insight into future of molecular approaches," *Molecular Cancer*, 21(1), p. 39. Available at: https://doi.org/10.1186/s12943-022-01513-z.

Zamora, E.A. and Alkherayf, F. (2024) *Ependymoma*.